News Archive
- Year 2017 (19 items)
- Year 2016 (37 items)
- GastroPanel® examination now possible from a whole blood sample
- Biohit Oyj’s Financial Reporting and Annual General Meeting in 2017
- Biohit Oyj’s Option Scheme I 2013 – Management Option Arrangement
- Biohit Oyj and R-kioski to start cooperation
- Biohit Oyj unveils groundbreaking GastroPanel® quick test
- Acetium capsule prevents the exposure to carcinogenic acetaldehyde in patients with atrophy of the stomach mucosa
- Biohit Oyj’s Chinese joint venture to start production - Gastric cancer risk screening study progressing in China
- The first meta-analysis of the scientific studies conducted with GastroPanel® has been completed – the test is accurate for diagnosing atrophic gastritis
- Glomedics to distribute Biohit Lactose Intolerance Quick Test in South Korea
- Ilari Patrakka appointed Biohit Oyj’s Sales and Marketing Director
- Beijing HuayiHuilang Medical Instrument Co., Ltd. to distribute GA-mapTM Dysbiosis Test in China
- BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2016
- Simultaneous testing of GastroPanel® biomarkers is possible – preliminary study results have been completed
- GastroPanel® detects risk factors of gastric cancer – a population-based screening study in Russia has been completed
- Vitamin B12 deficiency remains undetected and untreated far too often particularly among elderly citizens
- Beijing HuayiHuilang Medical Instrument Co., Ltd. to distribute Biohit Celiac Disease Quick Test in China
- Biohit Oyj and Pyynikin Craft Brewery to start cooperation
- Changes to Biohit Oyj’s Management Team
- Biohit Oyj Stock Options I 2013 will be registered in the Finnish book-entry system
- More scientific evidence on GastroPanel® test – the test predicts gastric cancer risk even at 15-year follow-up
- Pooyandegan Pezeshki Pardis to distribute Biohit GastroPanel®-test in Iran
- Atrophic gastritis and vitamin B12 deficiency remain often undetected in elderly people – early diagnosis is important to prevent complications
- Constitutive meeting of Biohit Oyj’s Board of Directors
- Decisions of the Annual General Meeting of Biohit Oyj
- Biohit Oyj starts inviting participants in the confirmatory smoking intervention trial
- The scientific report on Biohit’s first smoking intervention trial has been accepted for publication
- Helicobacter pylori infection increases the risk for gastric cancer – Long-term follow-up of the screened population has been completed
- NOTICE OF BIOHIT OYJ’S ANNUAL GENERAL MEETING
- Publication of Biohit Oyj Annual Report 2015
- Biohit and Tianjin Jingsheng Biological Technology Development Co. Ltd. to start co-operation
- Biohit and OnSite Diagnostic Labs India Pvt Ltd. to start co-operation
- BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2015
- Biohit Oyj’s Option Scheme I 2013 – International Sales Management Option Arrangement
- Biohit Oyj starts a confirmatory smoking intervention trial
- Biohit Oyj’s new B-shares have been registered with the Trade Register as a part of the share exchange agreement with Genetic Analysis AS
- Genetic Analysis AS general meeting has approved the share exchange with Biohit Oyj
- Biohit Oyj buys a share of Norwegian Genetic Analysis AS company with a directed share issue
- Year 2015 (39 items)
- Biohit Oyj will change its financial reporting – in the future, the company will publish financial reviews twice a year
- Biohit Oyj’s Management Team Option Arrangement
- Biohit's Financial Reporting and Annual General Meeting in 2016
- Acetium® is used in a Japanese cancer study – according to Professor Katsunori Iijima, the product can be a significant way to prevent cancer
- Colorectal screening project to start in Russia with Biohit Oyj’s ColonView test
- Acetium lozenge – a promising novel method to assist smoking cessation
- Vitamin D test to complement the diagnostics for osteoporosis and bone fracture prevention
- BIOHIT GROUP INTERIM REPORT Q3-2015
- Biohit Oyj launches a new version of its GastroPanel test
- European parliament’s expert consultation on acetaldehyde
- Promising results with Acetium lozenge in the elimination of carcinogenic acetaldehyde in saliva
- Biohit Oyj signed a distributor agreement with Daiichi Sankyo
- Acetium family grows during September
- BIOHIT GROUP INTERIM REPORT Q2-2015
- Biohit Oyj B-shares Subscribed with Stock Options I 2013 B
- Population-based screening study of asymptomatic persons to start in China using GastroPanel biomarkers disclosing gastric cancer risk
- Gastric cancer risk screening study to start in China
- Biohit Oyj B-shares Subscribed with Stock Options II 2013
- Biohit Oyj expands the distribution of Acetium® lozenge to dental care
- Modern colorectal cancer screening test on the market from Finland
- BIOHIT GROUP INTERIM REPORT Q1-2015
- European Parliament urges the Commission to immediately ask the European Food Safety Authority (EFSA) to re-evaluate the use of acetaldehyde
- Mekalasi Oy to distribute Biohit Quick Tests in Finland
- Constitutive meeting of Biohit Oyj’s Board of Directors
- Decisions of the Annual General Meeting of Biohit Oyj
- Acetaldehyde safety concerns
- Effortless accuracy with Biohit Quick Test Reader
- Acetaldehyde - a major pathophysiologic factor in gastric carcinogenesis
- Recommendations for detection of gastric cancer risk and monitoring of the cancer precursors
- Biohit Oyj B-shares Subscribed with Stock Options II 2013
- Publication of Biohit Oyj Annual Report 2014
- Biohit and Gulf Drug to sign a distributor agreement
- CORRECTION: NOTICE OF BIOHIT OYJ’S ANNUAL GENERAL MEETING
- Notice of Biohit OYJ’s Annual General Meeting
- Biohit and Oriola to distribution agreement
- Biohit Group Financial Statement Release 2014
- BIOHIT ColonView is the best colorectal cancer screening test on the market
- Biohit Oyj and Akeso to sign an Acetium distribution agreement in Russia
- Biohit and Ympyrätalo Pharmacy to co-operation
- Year 2014 (29 items)
- Biohit and Eurobio to sign a distributor agreement
- Biohit and Doctagon to co-operation
- Biohit Oyj B-shares Subscribed with Stock Options II 2013
- Biohit's Financial Reporting and Annual General Meeting in 2015
- Biohit re-launches ColonView – test for colorectal cancer screening
- Changes to Biohit Oyj’s management
- Biohit Oyj B-shares Subscribed with Stock Options II 2013
- BIOHIT GROUP INTERIM REPORT Q3-2014
- The efficacy of Acetium® capsule in treatment of atrophic gastritis is studied in China
- WHO prompts Helicobacter pylori screening to prevent gastric cancer
- Biohit Oyj B-shares Subscribed with Stock Options II 2013
- Changes to Biohit Oyj’s management
- Biohit Group Interim Report Q2-2014
- Biohit Oyj and Eastar Pharmaceuticals LLC to sign an Acetium® lozenge distribution agreement
- Chinese Health Associations give consensus clause on early gastric cancer screening with GastroPanel entity
- Biohit Oyj and Giraffes Pharmaceutical Co. to sign an Acetium distribution agreement
- Biohit appoints Quick Test distributor in Germany
- Biohit Oyj B-shares Subscribed with Stock Options I and II 2013
- The European Commission’s response to the question of food acetaldehyde by MEP Sirpa Pietikäinen
- Biohit Oyj launches new Biohit Active B12 test to diagnosis of B12 vitamin deficiency
- Enrollment to clinical trials for prevention of migraine-type headache
- BIOHIT GROUP INTERIM REPORT Q1-2014
- Promising results with Acetium capsule in the treatment of low acid and acid-free stomach in Italian study
- Acetium® results in international meeting for Gastroenterology – excellent results on Acetium® capsule repeated in Sweden
- Acetium® results in international meeting for Gastroenterology - excellent results on Acetium® capsule repeated in Japan
- Biohit online shop now available for deliveries throughout the EU
- Biohit Oyj starts two clinical trials with Acetium® capsule for prevention of migraine-type headache
- Biohit measured the cavas from Helsingin Sanomat rating – alcohol researcher comments
- Decisions of the Annual General Meeting of Biohit Oyj
- Year 2013 (6 items)
- Biohit Oyj to establish Joint Venture in China - Biohit Biotech (Hefei) Co., Ltd.
- Biohit to partner with Ferring Pharmaceuticals
- Biohit announces the results of acetaldehyde measurements in commercial quarks and soy sauces
- Leaders in Gastroenterology propose a rational for the non-invasive screening of Atrophic Gastritis using stomach-specific biomarkers.
- Biohit Healthcare moves to the North West
- Biohit OYJ completes the sale of its Liquid Handling business
- Year 2012 (0 item)
- Year 2011 (3 items)
- Year 2010 (15 items)
- Biohit Oyj to issue convertible bond
- Changes in Biohit Oyj's Management Team
- New President and CEO for Biohit Oyj
- New Acetium capsule designed to reduce carcinogenic acetaldehyde
- Amendments to the Article of Association of Biohit Oyj come into power today
- Interim report of the Biohit Group 1 January to 31 March 2010
- NEW PCR Starter Kit from Biohit!
- Resolutions of the Annual General Meeting of Biohit Oyj
- Biohit's Annual report 2009 has been published
- Notice of Annual General Meeting of Shareholders of Biohit Oyj
- Biohit's Financial Statements and Report of the Board of Directors 2009
- New Liquid Handling Products Catalogue
- Biohit Group's Financial Statement Release 2009
- New Director appointed to Biohit's Diagnostics business
- New product for elimination of carcinogenic acetaldehyde - Acetium
- Year 2009 (2 items)
- Year 2008 (1 item)
- Year 2007 (1 item)
Chinmax Medical Systems Inc. to distribute Acetium® Lozenge in China
05.06.2017 09:30
Biohit Oyj press release 5 June 2017 at 9:30 am. local time (EEST)
Biohit Oyj and Chinmax Medical Systems Inc. have signed an agreement for the distribution of the Acetium lozenge in China. The agreement has been signed for a preliminary period of seven years and includes an option and a letter of intent for a joint venture arrangement and local production if the sales targets set out in the agreement are met.